Chiron Capital Management LLC Has $1.90 Million Stake in Pfizer Inc. $PFE

Key Points

• Chiron Capital Management LLC increased its stake in Pfizer Inc. by 24.4%, now holding 75,035 shares valued at approximately $1.90 million, making it the 10th largest position in their portfolio.
• Pfizer reported a net margin of 16.84% and revenue of $14.65 billion for the recent quarter, exceeding analyst estimates and reflecting a 10.3% increase compared to the same quarter last year.
• The company announced a quarterly dividend of $0.43 per share, yielding 7.0%, with a dividend payout ratio of 91.49%.

Chiron Capital Management LLC lifted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 24.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 75,035 shares of the biopharmaceutical company's stock after purchasing an additional 14,740 shares during the quarter. Pfizer accounts for approximately 1.7% of Chiron Capital Management LLC's holdings, making the stock its 10th biggest position. Chiron Capital Management LLC's holdings in Pfizer were worth $1,901,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of PFE. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $27,000. Gould Capital LLC boosted its stake in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer in the 1st quarter worth $27,000. North Capital Inc. purchased a new position in shares of Pfizer in the first quarter worth $28,000. Finally, Bayforest Capital Ltd bought a new position in shares of Pfizer during the first quarter valued at $28,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on PFE shares. Jefferies Financial Group upped their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. HSBC decreased their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. Bank of America raised their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Berenberg Bank decreased their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. Finally, Citigroup raised their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Stock Performance

Pfizer stock traded up $0.18 during trading on Tuesday, reaching $24.94. The company had a trading volume of 44,247,211 shares, compared to its average volume of 40,145,636. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $141.77 billion, a price-to-earnings ratio of 13.26, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. The firm's 50-day simple moving average is $24.82 and its 200 day simple moving average is $24.37.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer's dividend payout ratio is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.